ConductScience.org, home

Paper337083

[The toxicity of massive dosis of VM26 (4-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside). A contribution to the therapy of advanced ovarian cancer (author's transl)].

Jankowski RP and 1 other. Med Klin, 1977. Cited by 9 papers, by iCite.

Cite this record

ConductScience Library. [The toxicity of massive dosis of VM26 (4-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside). A contribution to the therapy of advanced ovarian cancer (author's transl)]. Papers, record 337083. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/337083

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
[The toxicity of massive dosis of VM26 (4-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside). A contribution to the therapy of advanced ovarian cancer (author's transl)].
PubMed
Journal
Med Klin
PubMed
Year
1977
PubMed
Publication types
Clinical Trial, English Abstract, Journal Article
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
0.59
iCite
Revised in PubMed
2013-11-21
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Jankowski RPR P
2Vahrson HH

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Ovarian NeoplasmsMajor topic
PodophyllotoxinMajor topic
TeniposideMajor topic
Aged
Clinical Trials as Topic
Drug Evaluation
Female
Humans
Leukopenia
Middle Aged
Nausea
Remission, Spontaneous
Vomiting

Source PubMed

Download CSV of topics

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
8070021Teniposide: overview of its therapeutic potential in adult cancers.Cancer Chemother Pharmacol1994https://conductscience.org/library/papers/8070021PubMed
7044593The podophyllotoxin derivatives VP16-213 and VM26.Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/7044593PubMed
6371015Developing new drugs for ovarian cancer: a challenging task in a changing reality.J Cancer Res Clin Oncol1984https://conductscience.org/library/papers/6371015PubMed
4017164Pharmacokinetics of teniposide (VM 26) after IV administration in serum and malignant ascites of patients with ovarian carcinoma.Cancer Chemother Pharmacol1985https://conductscience.org/library/papers/4017164PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/337083

GET https://conductscience.org/api/papers/v1/337083/authors